NEW YORK, NY / ACCESS Newswire / October 27, 2025 / If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ:CYTK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=174044&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

Follow-on draw affirms investor support for Capstone’s growth strategy and reflects the company’s disciplined approach to financing accretive acquisitions. NEW YORK, NY / ACCESS Newswire / October 27, 2025 / Capstone Holding Corp. (NASDAQ:CAPS), a national building products distribution platform, today announced a $3.25 million draw from its existing convertible note facility. This new tranche

Birmingham couple selected from 5,000+ submissions and 19 national finalists after public Instagram voting; two runners‑up honored Wed Society® today named Anna‑Kate and Spencer the 2025 National Wedding of the Year, the brand's top editorial honor celebrating aesthetic excellence and best‑in‑class vendor collaboration across its local franchise markets. Their winning celebration took place in Birmingham,

Complements Korea's Quantum Defense Strategy and fast-tracks commercialization of a next-generation quantum-secure secure-element chip (QCIM) for Defense, Critical Infrastructure, Internet of Things (IoT) devices, Payments, Mobile Authentication, AI and Digital Assets. — Deal and scope: BTQ signed a USD 15 million development and joint investment agreement with ICTK (KOSDAQ: 456010) to co-develop Quantum Compute in

Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placebo in the Phase 2b ANTHEM-UC study Results support Phase 3 clinical development of icotrokinra, a first-in-class targeted oral peptide that precisely blocks the IL-23 receptor, in both moderately to

Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies TREMFYA® is the only IL-23 inhibitor to demonstrate durable endoscopic and clinical remission with a fully subcutaneous regimen in moderately to severely active Crohn's disease Johnson & Johnson (NYSE: JNJ) today announced

Allstate reports applications for new credit cards, loans and account setups peak in October during pre-Black Friday shopping, totaling more than $9M in potential losses Key takeaways: — October kicks offidentity theft season, with the highest volume of fraudulent credit and loan applications all year. — Fraud applications account for nearly 70% of all identity

The Canadian economy is expected to see slow growth in Q3 and Q4 2025, finds the Canadian Federation of Independent Business's (CFIB) latestMain Street Quarterlyreport. Key highlights of the Q3 2025 edition of the Main Street Quarterly report — CFIB's estimates and forecasts in partnership with AppEco suggest Canadian economy grew by 0.8% in Q3

NEW YORK, NY / ACCESS Newswire / October 27, 2025 / If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ:MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=174046&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / October 27, 2025 / If you suffered a loss on your LifeMD, Inc. (NASDAQ:LFMD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lifemd-inc-lawsuit-submission-form?prid=174047&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call